Primpex DS

Primpex DS (Double Strength) is a potent combination antibacterial medication containing sulfamethoxazole and trimethoprim (also known as co-trimoxazole). It works through a sequential dual-blockade of bacterial folic acid synthesis. Sulfamethoxazole inhibits the formation of dihydrofolic acid, while trimethoprim blocks its reduction to tetrahydrofolic acid—an essential cofactor for bacterial DNA and protein synthesis. This synergistic action converts two bacteriostatic agents into a powerful, broad-spectrum bactericidal treatment.

Primary Medical Indications

Primpex DS is indicated for adult and pediatric patients (above 12 years) for a wide range of bacterial infections, including:

• Urinary Tract Infections (UTIs): Uncomplicated and complicated cystitis, pyelonephritis, and recurrent UTI prophylaxis caused by susceptible strains of E. coli, Klebsiella, or Enterobacter.

• Respiratory Tract Infections: Acute exacerbations of chronic bronchitis, otitis media in pediatric patients, and treatment or prevention of Pneumocystis jirovecii pneumonia (PJP/PCP) in immunocompromised patients.

• Gastrointestinal Infections: Shigellosis (bacillary dysentery), traveler’s diarrhea caused by enterotoxigenic E. coli, and cholera (as an adjunct).

• Other Indications: Nocardiosis and certain skin/soft tissue infections caused by community-acquired Methicillin-Resistant Staphylococcus aureus (MRSA).

Key Product Specifications & Dosing Forms

Important Safety & Administration Guidelines

• Sulfa Allergy Warning: Strictly contraindicated in patients with a known hypersensitivity to sulfonamides, trimethoprim, or chemically related drugs (e.g., thiazide diuretics, sulfonylureas).

• Severe Skin Reactions: Discontinue immediately at the first sign of a skin rash or mucosal lesion, as co-trimoxazole has been associated with rare but severe reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).

• Hydration Requirement: Patients should maintain adequate fluid intake during treatment to minimize the risk of renal calculus formation and crystalluria.

• Hematologic Monitoring: Exercise caution in patients with folate deficiency, severe renal or hepatic impairment, or elderly individuals. Periodic blood counts may be warranted during extended therapy.